These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10871860)

  • 1. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
    Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
    Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
    Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P; Robey R; Fojo T; Blagosklonny MV
    Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
    Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
    Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
    Bartussek C; Naumann U; Weller M
    Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
    Balachandran R; Welsh MJ; Day BW
    Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
    Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
    Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
    Ling YH; Zou Y; Perez-Soler R
    Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
    Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil.
    Johnson KR; Fan W
    Anticancer Res; 2002; 22(6A):3197-204. PubMed ID: 12530065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1.
    Drago-Ferrante R; Santulli A; Di Fiore R; Giuliano M; Calvaruso G; Tesoriere G; Vento R
    Int J Oncol; 2008 Oct; 33(4):677-87. PubMed ID: 18813780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S; McCauley RA; Dexter DW; Hudes GR
    Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular models of drug- and radiation-resistant small cell lung cancer.
    Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
    Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
    Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
    Banerjee A
    Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.
    Dey S; Spring PM; Arnold S; Valentino J; Chendil D; Regine WF; Mohiuddin M; Ahmed MM
    Clin Cancer Res; 2003 Apr; 9(4):1557-65. PubMed ID: 12684432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.